Supplementary Figure 16 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma

Supplementary Figure 16. Comparison of gut microbiome profiles in MM patients from the first cohort at baseline (apheresis day) and 12 months post–CAR-T-cell infusion. (A) Principal coordinates analysis (PCA) of bacterial community composition at baseline (apheresis day) vs 12 months post CAR-T cell infusion microbiome in MM patients. (B) Variable importance in projection (VIP) scores from partial least square-discriminant analysis (PLS-DA) identifying the top 10 discriminating parameters from 16sRNA metagenomics. Scores plot of PLS-DA based on metagenomics of samples 12 months post-infusion (purple, n = 4) and at baseline (blue, n = 4) from paired patients. Colored dots illustrate individual samples. Axes are labeled with the first and second components and their respective percentages of explained variance.